ArticleProceedings of the National Academy of Sciences of the United States of America2024
CD38-RyR2 axis-mediated signaling impedes CD8
Open access · hybridAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma.Blood advances · 2025Trial
- Dual control of liver regeneration by Nr1d1 homeostasis and Klf2 checkpoint.Cell death discovery · 2026Article
- Ion-Channel-Mediated Drug Repurposing Opportunities Validated by Single-Cell Perturbation in Colorectal Cancer.International journal of molecular sciences · 2026Article
- Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.Nature medicine · 2026Article
- S1P-S1PR1 signaling impairs CD8EMBO reports · 2026Article
- Phenotype of circulating tumor-reactive T cells predicts immune checkpoint inhibitor response in non-small cell lung cancer.Nature communications · 2026Article
- Prediction of severe sepsis-associated acute kidney injury incorporating immune-inflammatory profiles: development and validation of a machine learning model in a multicenter prospective cohort study.Frontiers in immunology · 2026Article
- Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases.Histopathology · 2025Article
- Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer.iScience · 2025Article
- Novel loop structure of human IgG1 Fc fused CD38 targeted bispecific antibodies and their anti-tumor effect in acute myeloid leukemia.Journal of translational medicine · 2025Article
- Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants.Cell reports. Medicine · 2025Article
- CD38-mediated metabolic reprogramming promotes the stability and suppressive function of regulatory T cells in tumor.Science advances · 2025Article
- Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function.Molecular therapy. Oncology · 2024Article
- CD38-RyR2 axis-mediated signaling impedes CD8Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy.Oncoimmunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Anwesha KarDivision of Cancer Biology and Inflammatory Disorder, Translational Research Unit of Excellence, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.ORCID 0000-0002-4455-6276
Puspendu GhoshDivision of Cancer Biology and Inflammatory Disorder, Translational Research Unit of Excellence, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.ORCID 0000-0003-0920-2306
Anupam Gautam *Algorithms in Bioinformatics, Institute for Bioinformatics and Medical Informatics, University of Tübingen, Sand 14 72076, Tübingen, Baden-Württemberg, Germany.ORCID 0000-0002-6460-6525
Snehanshu Chowdhury *Division of Cancer Biology and Inflammatory Disorder, Translational Research Unit of Excellence, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.
Debashree BasakDivision of Cancer Biology and Inflammatory Disorder, Translational Research Unit of Excellence, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.
Ishita SarkarDivision of Cancer Biology and Inflammatory Disorder, Translational Research Unit of Excellence, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.
Arpita BhoumikDivision of Cancer Biology and Inflammatory Disorder, Translational Research Unit of Excellence, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.
Shubhrajit BarmanAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India.ORCID 0009-0006-0981-4424
Paramita ChakrabortyDepartment of Surgery, Medical University of South Carolina, Charleston, South Carolina SC- 29425.
Asima MukhopadhyayKolkata Gynaecology Oncology Trials and Translational Research Group, Kolkata 700156, West Bengal, India.ORCID 0000-0003-0761-9562
Shikhar MehrotraDepartment of Surgery, Medical University of South Carolina, Charleston, South Carolina SC- 29425.
Senthil Kumar GanesanDivision of Structural Biology & Bioinformatics, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.
Sandip PaulSystem Biology Informatics Lab, Center for Health Science and Technology, JIS Institute of Advanced Studies and Research, JIS University, Kolkata 700091, West Bengal, India.ORCID 0000-0001-7406-3598
Shilpak ChatterjeeDivision of Cancer Biology and Inflammatory Disorder, Translational Research Unit of Excellence, Council of Scientific and Industrial Research-Indian Institute of Chemical Biology, Kolkata 700032, West Bengal, India.
Indian Institute of Chemical Biology · INMedical University of South Carolina · USCalcutta Research Group · INMax Planck Institute for Biology · DE
Funding
Anti-oxidant and Metabolic Phenotype in Regulating Tumor Specific T cell Memory ResponseR01CA236379 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2020 to 2024
$2.5MUnderstanding Metabolic and Epigenetic Cross‐ talk in Potent Anti‐ tumor T cellsR01CA250458 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MEHROTRA, SHIKHAR · 2020 to 2024
$2.3MProgramming Metabolically Fit TILs for ImmunotherapyR42CA239952 · NCI · LIPO-IMMUNO TECH, LLC · PI MEHROTRA, SHIKHAR · 2023 to 2024
$2.0MProgramming Metabolically Fit TILs for ImmunotherapyR41CA239952 · NCI · LIPO-IMMUNO TECH, LLC · PI MEHROTRA, SHIKHAR · 2020 to 2020
$225kDBT-Wellcome Trust India Alliance IA/I/19/1/504277NCI NIH HHS R01 CA236379NCI NIH HHS R01 CA250458NCI NIH HHS R41 CA239952NCI NIH HHS R42 CA239952Wellcome Trust
Abstract
PD1 blockade therapy, harnessing the cytotoxic potential of CD8
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAnimalsMiceProto-Oncogene Proteins c-aktRyanodine Receptor Calcium Release ChannelT-Lymphocyte SubsetsProto-Oncogene Proteins c-aktRyanodine Receptor Calcium Release Channelanti-PD1 resistanceCD38T cell exhaustion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.